KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Quest Diagnostics (DGX) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Quest Diagnostics (DGX) over the last 17 years, with Q3 2025 value amounting to $432.0 million.

  • Quest Diagnostics' Cash & Equivalents fell 4345.55% to $432.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $432.0 million, marking a year-over-year decrease of 4345.55%. This contributed to the annual value of $549.0 million for FY2024, which is 1997.08% down from last year.
  • Per Quest Diagnostics' latest filing, its Cash & Equivalents stood at $432.0 million for Q3 2025, which was down 4345.55% from $319.0 million recorded in Q2 2025.
  • In the past 5 years, Quest Diagnostics' Cash & Equivalents ranged from a high of $1.2 billion in Q1 2021 and a low of $126.0 million during Q2 2023
  • Moreover, its 5-year median value for Cash & Equivalents was $549.0 million (2024), whereas its average is $541.7 million.
  • In the last 5 years, Quest Diagnostics' Cash & Equivalents plummeted by 8405.06% in 2023 and then skyrocketed by 43426.57% in 2024.
  • Quarter analysis of 5 years shows Quest Diagnostics' Cash & Equivalents stood at $872.0 million in 2021, then crashed by 63.88% to $315.0 million in 2022, then skyrocketed by 117.78% to $686.0 million in 2023, then dropped by 19.97% to $549.0 million in 2024, then decreased by 21.31% to $432.0 million in 2025.
  • Its Cash & Equivalents stands at $432.0 million for Q3 2025, versus $319.0 million for Q2 2025 and $188.0 million for Q1 2025.